Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.
You may also be interested in...
Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.
US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.
Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.